UBS Group’s Grace Therapeutics GRCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $38.1K | Sell |
16,777
-9,524
| -36% | -$26.4K | ﹤0.01% | 7735 |
|
|
2026
Q1 | $122K | Buy |
+26,301
| New | +$103K | ﹤0.01% | 6905 |
|
|
2024
Q4 | – | Sell |
-28
| Closed | -$84 | – | 10568 |
|
|
2024
Q3 | $84 | Sell |
28
-7,707
| -100% | -$20.6K | ﹤0.01% | 9177 |
|
|
2024
Q2 | $22.6K | Buy |
7,735
+5,788
| +297% | +$17.5K | ﹤0.01% | 7228 |
|
|
2024
Q1 | $6.67K | Sell |
1,947
-3,655
| -65% | -$10.8K | ﹤0.01% | 7447 |
|
|
2023
Q4 | $16.2K | Buy |
5,602
+890
| +19% | +$2.11K | ﹤0.01% | 7230 |
|
|
2023
Q3 | $13.1K | Buy |
+4,712
| New | +$11.2K | ﹤0.01% | 6998 |
|
|
2023
Q2 | – | Sell |
-624
| Closed | -$1.72K | – | 9804 |
|
|
2023
Q1 | $1.72K | Buy |
+624
| New | +$2.23K | ﹤0.01% | 8662 |
|
|
2022
Q4 | – | Sell |
-4,048
| Closed | -$14K | – | 11237 |
|
|
2022
Q3 | $14K | Buy |
+4,048
| New | +$19.9K | ﹤0.01% | 7939 |
|
|
2022
Q2 | – | Sell |
-198
| Closed | -$1K | – | 11066 |
|
|
2022
Q1 | $1K | Buy |
+198
| New | +$1.41K | ﹤0.01% | 9953 |
|
|
2021
Q4 | – | Sell |
-750
| Closed | -$9K | – | 10815 |
|
|
2021
Q3 | $9K | Buy |
750
+206
| +38% | +$4.06K | ﹤0.01% | 8125 |
|
|
2021
Q2 | $15K | Buy |
+544
| New | +$13.3K | ﹤0.01% | 7656 |
|
|
2020
Q3 | – | Sell |
-402
| Closed | -$9K | – | 8484 |
|
|
2020
Q2 | $9K | Sell |
402
-742
| -65% | -$21.6K | ﹤0.01% | 7101 |
|
|
2020
Q1 | $21K | Buy |
1,144
+998
| +684% | +$35.3K | ﹤0.01% | 6471 |
|
|
2019
Q4 | $17K | Buy |
146
+68
| +87% | +$6.72K | ﹤0.01% | 7007 |
|
|
2019
Q3 | $7K | Sell |
78
-188
| -71% | -$17.4K | ﹤0.01% | 7356 |
|
|
2019
Q2 | $15K | Sell |
266
-287
| -52% | -$12.6K | ﹤0.01% | 6817 |
|
|
2019
Q1 | $27K | Buy |
+553
| New | +$27.3K | ﹤0.01% | 6043 |
|
|
2018
Q3 | – | Sell |
-94
| Closed | -$3K | – | 8327 |
|
|
2018
Q2 | $3K | Buy |
94
+73
| +348% | +$2.81K | ﹤0.01% | 7659 |
|
|
2018
Q1 | $1K | Sell |
21
-369
| -95% | -$18.2K | ﹤0.01% | 7677 |
|
|
2017
Q4 | $18K | Buy |
+390
| New | +$26.2K | ﹤0.01% | 6637 |
|
|
2017
Q1 | – | Sell |
-69
| Closed | -$4K | – | 8048 |
|
|
2016
Q4 | $4K | Buy |
69
+47
| +214% | +$3.16K | ﹤0.01% | 7342 |
|
|
2016
Q3 | $2K | Buy |
+22
| New | +$1.63K | ﹤0.01% | 7428 |
|
|
2016
Q2 | – | Sell |
-75
| Closed | -$5K | – | 8023 |
|
|
2016
Q1 | $5K | Buy |
75
+39
| +108% | +$3.06K | ﹤0.01% | 7018 |
|
|
2015
Q4 | $4K | Buy |
36
+3
| +9% | +$354 | ﹤0.01% | 7798 |
|
|
2015
Q3 | $4K | Sell |
33
-2
| -6% | -$335 | ﹤0.01% | 7854 |
|
|
2015
Q2 | $5K | Buy |
+35
| New | +$6.51K | ﹤0.01% | 7887 |
|
|
2015
Q1 | – | Sell |
-28
| Closed | -$7K | – | 9478 |
|
|
2014
Q4 | $7K | Buy |
+28
| New | +$6.89K | ﹤0.01% | 8734 |
|
Other funds holding GRCE
EP
MS
BC
CF
UBS Group's GRCE Position: Q2 2026 in Review
UBS Group reduced its Grace Therapeutics (GRCE) stake by 36% in Q2 2026, selling an estimated $26.4K and leaving 16,777 shares worth $38.1K. The position accounts for ﹤0.01% of the portfolio, ranked #7735.
UBS Group first reported a position in GRCE in Q4 2014 and has held it in 28 quarters since. The position peaked at $122K in Q1 2026. 33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.
- UBS Group held 16,777 shares of Grace Therapeutics worth $38.1K as of Q2 2026.
- UBS Group sold 9,524 Grace Therapeutics shares in Q2 2026, an estimated $26.4K.
- Grace Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7735 holding.
- UBS Group first reported a position in Grace Therapeutics in Q4 2014 and has held it in 28 quarters since.
- UBS Group's Grace Therapeutics position peaked at $122K in Q1 2026.
- 33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.